A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) has a poor prognosis and high mortality.
• TNBC exhibits elevated programmed cell death ligand 1 (PD-L1) expression, suppressing CD8+ T cell activity in the tumor microenvironment.
• Inhibitors of apoptosis proteins (IAPs) regulate cell death by inhibiting caspase activity.

Purpose of the Study:

• To investigate the therapeutic potential of Birinapant, an IAP antagonist, in TNBC.
• To evaluate the combination therapy of Birinapant and siPD-L1 for TNBC treatment.

Main Methods:

• Assessed Birinapant's effect on CD8+ T cell infiltration via CXCL9 secretion.
• Evaluated Birinapant's impact on tumor growth, TNF-α secretion, and sensitivity in a TNBC xenotransplantation mouse model.
• Investigated the efficacy of liposomal combination therapy with Birinapant and siPD-L1.

Main Results:

• Birinapant promoted CD8+ T cell infiltration by increasing CXCL9 secretion.
• Birinapant inhibited tumor growth by enhancing TNF-α secretion and sensitivity.
• The combination therapy of Birinapant and siPD-L1 significantly improved therapeutic effects in TNBC.

Conclusions:

• Birinapant enhances anti-tumor immunity and inhibits tumor growth in TNBC models.
• Combination therapy using Birinapant and siPD-L1 demonstrates significant therapeutic potential for TNBC.